Homepage > Company > Media > Pharma News > 2016 > Opdivo approved quickly for first hematological cancer

Opdivo approved quickly for first hematological cancer

FDA granted accelerated approval to Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat classical Hodgkin's lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and treatment with Adcetris brentuximab vedotin. BMS said Opdivo is the first FDA-approved PD-1 inhibitor for a hematological malignancy.

The approval came well ahead of Opdivo's Sept. 1 PDUFA date in the indication, for which it has breakthrough therapy and Orphan Drug designations.

BMS markets Opdivo to treat metastatic non-small cell lung cancer (NSCLC), advanced renal cell carcinoma (RCC) and melanoma. Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) market Adcetris, an antibody-drug conjugate (ADC) composed of an anti-CD30 mAb and monomethyl auristatin E (MMAE).

Published on Tuesday, May 17, 2016

Source: http://www.biocentury.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)